Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Carvykti (ciltacabtagene autoleucel)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

J&J, Legend Biotech

Drug class:

BCMA-targeted CAR-T immunotherapy

Related drugs:

‹

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: A1 - Approval J&J Press Release - 1 week (New A1) ciltacabtagene autoleucel Sensitive : A1 J&J Press Release - 1wk	ciltacabtagene autoleucel Sensitive: A1 - Approval J&J Press Release - 1 week ciltacabtagene autoleucel Sensitive : A1 J&J Press Release - 1 week - (New A1)
TNFRSF17 overexpression	Multiple Myeloma	TNFRSF17 overexpression	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3